BACKGROUND: Across the world, antibiotic resistance is a grave problem.
AIM OF THE STUDY: To explore Egypt's diverse soil habitats for the production of bacterial Myxopyronin B, which is then tested for antimicrobial activity in preclinical animal studies and randomized human clinical trials stages 1/2.
METHODOLOGY: Egypt's various soil conditions were examined for the development of bacterial isolates that produced the antibiotic compound Myxopyronin B.  To determine the test antibiotic's minimum inhibitory concentration [MIC] and in vitro antibacterial activity, the Broth microdilution method and the Paper disc diffusion assay were utilized. Moreover, in vivo antibacterial spectrum, adverse medication responses, and pharmacokinetics were found in preclinical animal testing stages; as well as phases 1/2 of randomized clinical studies involving 150 volunteer humans from both secs with ages ranging from 5-60 years old.
RESULTS: Myxopyronin B was generated from the culture supernatant of Myxococcus SDU36, the main soil bacterial isolate cultured on a Casein yeast peptone plate. With MICs less than 100 mcg/ml, the test antibiotic prevented the growth of several Gram +ve bacteria, whereas, at MICs higher than 100 mcg/ml, it inhibited the growth of a small number of Gram -ve bacteria, including Escherichia coli.  However, eukaryotic cells—such as those found in fungi and humans—were unaffected.  The test antibiotic was seen to inhibit prokaryotic DNA-dependent RNA polymerase [RNLP], indicating its bactericidal activity. Mean Cmax was 9-10 mcg/ ml at mean Tmax 1 hour when 600 mg dose was orally administered in randomized human clinical trials phases 1/2; as well as T1/2 reached 2.25 hours following first-order kinetics of elimination. The duration of its action was nearly 8 hours after oral administration.
CONCLUSION: The present study was promising due to the production of the bactericidal antibiotic Myxopyronin B from Myxococcus sp. SDU36 isolated from different soil environments in Egypt.